9 studies found for:    Reslizumab | asthma | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
Condition: Asthma
Interventions: Drug: Reslizumab;   Drug: Placebo
2 Recruiting An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
Conditions: Asthma;   Elevated Blood Eosinophils
Interventions: Drug: Reslizumab;   Drug: Placebo
3 Completed A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Placebo
4 Terminated Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Intervention: Drug: Reslizumab
5 Completed A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Placebo
6 Completed Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Matching Placebo
7 Completed A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
Condition: Eosinophilic Asthma
Interventions: Drug: Reslizumab;   Drug: Placebo
8 Enrolling by invitation Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
Conditions: Severe Persistent Asthma;   Eosinophilic Bronchitis
Interventions: Biological: Reslizumab;   Drug: Placebo
9 Completed Cross-sectional Study for Identification and Description of Severe Asthma Patients
Condition: Asthma
Intervention: Drug: Short Acting Beta Agonist (SABA)

Indicates status has not been verified in more than two years